About Allos Therapeutics, trial, which Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs to treat cancer. The company principal, pralatrexate, is a novel targeted antifolate designed to preferentially accumulate in cancer cells. In February 2009 the Company announced the final results from PROPEL, the company’s pivotal Phase 2 trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma generic sildenafil citrate uk here . The PROPEL under an agreement under an agreement with the U.S. Food and Drug Administration under its Special Protocol Assessment process reached. Based on the results of the PROPEL trial, which in March 2009 the company submitted a New Drug Application to the FDA for the use of pralatrexate for the treatment of patients with relapsed or refractory PTCL. The company examines pralatrexate in patients with peripheral T – cell lymphoma, non-small cell lung cancer, bladder cancer, and a range of lymphoma subtypes In some cases the exclusive worldwide rights to pralatrexate for all indications. For more information, please visit. SourceAllos Therapeutics.
This information was out of globalhealth.org by courtesy the Henry J. Kaiser the Henry J. Kaiser Family Foundation They can view the entire Kaiser Daily Globalhealth policy coverage looking in archives and sign up on email delivery at Globalhealth.